326030 Financial Statements From 2010 to 2024
| 326030 Stock | 106,300 1,100 1.05% |
Check Sk Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sk Biopharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . 326030 financial statements analysis is a perfect complement when working with Sk Biopharmaceutica Valuation or Volatility modules.
326030 |
Sk Biopharmaceuticals Co Company Current Valuation Analysis
Sk Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sk Biopharmaceutica Current Valuation | 5.87 T |
Most of Sk Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sk Biopharmaceuticals Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sk Biopharmaceuticals Co has a Current Valuation of 5.87 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
Sk Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sk Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Sk Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sk Biopharmaceutica competition to find correlations between indicators driving Sk Biopharmaceutica's intrinsic value. More Info.Sk Biopharmaceuticals Co is rated fifth in return on equity category among its peers. It is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sk Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sk Biopharmaceutica's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Sk Biopharmaceutica Financial Statements
Sk Biopharmaceutica stakeholders use historical fundamental indicators, such as Sk Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sk Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sk Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on Sk Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sk Biopharmaceuticals Co. Please read more on our technical analysis and fundamental analysis pages.
Pair Trading with Sk Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sk Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with 326030 Stock
Moving against 326030 Stock
The ability to find closely correlated positions to Sk Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sk Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sk Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sk Biopharmaceuticals Co to buy it.
The correlation of Sk Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sk Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sk Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sk Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in 326030 Stock
Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.